Nomura Holdings’s Starling Oncology, Inc. Warrant STLNW Stock Holding History

Nomura Holdings’s Portfolio STLNW Stock Details STLNW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-8,375	Closed	-$12K	–	2471
2021 Q3	$12K	Hold	8,375	–	–	﹤0.01%	1927
2021 Q2	$15K	Buy	+8,375	New	+$11.3K	﹤0.01%	1936

Other funds holding STLNW

LMR Partners London, United Kingdom $45.4B AUM 60.47% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

HCM

Highbridge Capital Management New York $3.09B AUM 31.21% 1-Year Est. Return

DKCM

Davidson Kempner Capital Management New York $7.33B AUM 56.47% 1-Year Est. Return

Jefferies Group New York $12B AUM 6.2% 1-Year Est. Return

DCM

Difesa Capital Management New York $38.1M AUM 39.86% 1-Year Est. Return

USPCM

Union Square Park Capital Management New York $176M AUM 51.52% 1-Year Est. Return

WAM

Wolverine Asset Management Chicago, Illinois $10.4B AUM 4.78% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Man Group London, United Kingdom $55.1B AUM 24.23% 1-Year Est. Return

Nomura Holdings's STLNW Position: Q4 2021 in Review

Nomura Holdings sold out of Starling Oncology, Inc. Warrant (STLNW) in Q4 2021, closing a stake of 8,375 shares — an estimated $12K sold.

Nomura Holdings first reported a position in STLNW in Q2 2021 and held it in 2 quarters. The position peaked at $15K in Q2 2021. 20 funds tracked by Wall St. Rank hold STLNW as of Q4 2021.

Nomura Holdings reported no remaining Starling Oncology, Inc. Warrant position as of Q4 2021 after selling out during the quarter.
Nomura Holdings sold 8,375 Starling Oncology, Inc. Warrant shares in Q4 2021, an estimated $12K.
Nomura Holdings first reported a position in Starling Oncology, Inc. Warrant in Q2 2021 and held it in 2 quarters.
Nomura Holdings's Starling Oncology, Inc. Warrant position peaked at $15K in Q2 2021.
20 funds tracked by Wall St. Rank held Starling Oncology, Inc. Warrant as of Q4 2021.

Based on Nomura Holdings's 13F filing for Q4 2021, filed 14 Feb 2022.